Healthcare Professionals Interest in neffy: A Self-Administered Epinephrine Nasal Spray Device

¹ St. Paul Allergy & Asthma, P.A., St. Paul, MN; ² Howard University Hospital, Washington, DC; ³ University of Colorado Health Sciences Center, Denver, CO; ⁴Bernstein Allergy Group, Cincinnati, OH; ⁵Spinnaker Life Science, Boston, MA; ⁶ARS Pharmaceuticals, San Diego, CA.

RATIONALE

- Epinephrine autoinjectors (EAIs) are the most common method for out-of-hospital epinephrine administration during severe allergic reactions.
- However, patients/caregivers frequently fail to dose or delay dosing, increasing the risk of complications, including hospitalization and death.
- neffy, a small, FDA-approved, needle-free epinephrine nasal spray device, is expected to reduce dosing hesitance and increase willingness to carry and use epinephrine when needed.

METHODS

- The objectives of the study were to measure health care provider (HCP) awareness, perceptions, and prescribing of existing treatments for patients with Type 1 allergic reactions, including anaphylaxis, and to establish baseline HCP awareness and perceptions of *neffy*.
- A 20-minute web-based survey designed to assess HCP perception of current EAIs as well as their interest in *neffy* was administered to 202 HCPs, including 104 allergists, 67 pediatricians, 10 primary care providers, and 21 nurse practitioner/physician assistants.
- The survey was blinded to the company sponsor.

RESULTS

- Respondents reported that the most common reasons patients failed to have or use EAIs were product affordability/accessibility (66%), fear of the needle (57%), and short shelf-life (56%) (Figure 1).
- After being presented with *neffy*, 74% of HCPs said they would be highly likely to prescribe the product, and 83% viewed the product more favorably than current treatments, citing *neffy*'s ease of administration (90%), data showing that the product is effective (74%), and improved portability (71%) (Figure 2).
- Ninety-four percent of HCPs said they would be highly likely to prescribe *neffy* for patients who fear injections, and 78% said they would definitely prescribe for patients at risk of non-compliance (refusing to/not taking their EAI when needed) (Figure 3).

Nicole M. Chase,¹ Autumn Burnette,² Daniel Soteres,³ Justin Greiwe,⁴ Harris Kaplan,⁵ Ayman Kafal⁶



Figure 1: Importance of the Attributes in an FDA Approved, On Market-Treatment for Patients with Type **1** Allergic Reactions Including Anaphylaxis

Patient affordability / accessibility 39 Needle-free mode of delivery (e.g., intranasal) 7% Treatment has a shelf life of 24+ months 39 Administration without hesitation (patient/caregiver willingness to use without waiting) Portability / size of device 10% Complete resolution of allergic reaction 22% Availability at patient's pharmacy 17% Treatment tolerability / palatability 12% Easy for patients to learn how to use correctly 11% Delivers a consistent dose reliably Treatment safety profile (Strongly) Agree (6 to 7) Home delivery option Neither Agree Nor Disagree (3-5) (Strongly) Disagree (1 to 2)

Figure 2: Main Reasons for Prescribing *neffy*

Ease of patient administration

Data showing that it works in patients with anaphylaxis

Ease of portability

Product stability and dating


PK and PD profile similar to needle injectors


Reliability of device


Onset of action

Proof that it works in patients with rhinitis

Adverse event profile 35%







CONCLUSION

- compliance.
- non-compliance.

Following the introduction of *neffy*, a majority of HCPs expressed a strong willingness to prescribe it due to its ease of use, efficacy, and enhanced patient

Healthcare providers found *neffy* favorable compared to current epinephrine autoinjectors, with 74% likely to prescribe it due to its ease of administration, effectiveness, and portability, particularly for patients fearing needles or at risk of

